✦ LIBER ✦

Cytosine arabinoside and cisplatin for advanced breast cancer. A phase II study of the cancer and leukemia group B

✍ Scribed by Martin W. Oster; Richard L. Schilsky; David Faraggi; Ann H. Korzun; Michael Perry; Ann Moore; Jagmohan Kalra; William C. Wood; I. Craig Henderson

Publisher: John Wiley and Sons
Year: 1991
Tongue: English
Weight: 207 KB
Volume: 68
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19911015)68:8<1696::aid-cncr2820680807>3.0.co;2-b

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study of peptichemio in advan

A phase II study of peptichemio in advanced breast cancer

✍ V. Hug; G. N. Hortobagyi; A. U. Buzdar; G. R. Blumenschein; W. Grose; M. A. Burg 📂 Article 📅 1980 🏛 John Wiley and Sons 🌐 English ⚖ 445 KB 👁 2 views

Phase II trial of cis-dichlorodiamminepl

Phase II trial of cis-dichlorodiammineplatinum (II) in advanced malignant lymphoma: A study of the cancer and acute leukemia group B

✍ F. Cavalli; Dr. W. F. Jungi; N. I. Nissen; T. F. Pajak; M. Coleman; J. F. Hollan 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 279 KB 👁 1 views

In a cooperative study of the Cancer and Acute Leukemia Group B, 27 evaluable patients with advanced malignant lymphomas were treated with 70 mg/m2 of cisdichlorodiammineplatinum(l1) (cis-platinum) once every three weeks. All patients had received extensive prior therapy. Partial remission was obtai

Dihydro-5-azacytidine and cisplatin in t

Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma : A phase II study by the Cancer and Leukemia Group B

✍ Brian L. Samuels; James Herndon II; David C. Harmon; Robert Carey; Joseph Aisner 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB 👁 1 views

## BACKGROUND. In a prior Cancer and Leukemia Group B (CALGB) Phase II trial of

A phase ii study of the combination of e

A phase ii study of the combination of etoposide and cisplatin in the therapy of advanced gastric cancer

✍ Thomas E. Elliott; Charles G. Moertel; Harry S. Wieand; Richard G. Hahn; James B 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 413 KB 👁 2 views

Forty-eight patients with advanced gastric cancer and measurable areas of malignant disease were treated with etoposide (130 mg/mz/day X 3 days) plus cisplatin (45 mg/mzday on days 2 and 3). Both drugs were given by constant intravenous infusion and repeated every 4 weeks. Common toxic reactions inc

Phase II study of a modified combination

Phase II study of a modified combination of etoposide, doxorubicin, and cisplatin for patients with advanced gastric cancer

✍ Içli, Fikri; Karaoguz, Handan; Akbulut, Hakan; Dinçol, Dilek; Demirkazik, Ahmet; 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 52 KB 👁 2 views

## Background: Based on the promising results of eap (etoposide, doxorubicin, and cisplatin) combination, a phase ii study of modified eap combination was performed in patients with advanced gastric cancer to evaluate the response, toxicity, and survival. ## Method: Fifty-two consecutive patients

A phase II study of combined 5-fluoroura

A phase II study of combined 5-fluorouracil and mitomycin C in advanced breast cancer

✍ Willy Mattsson; Finn Von Eyben; Lennart Hallsten; Göran Bjelkengren 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 340 KB 👁 2 views

In a Phase I1 study, 50 patients with advanced breast cancer were treated with a combination of 5fluorouracil(lOO0 mg/m2 on days 1 and 2) and mitomycin C (6 mg/m2 on day 2) (FuMi regimen). The courses were repeated every third to sixth week. Although 35 patients had previously received combination c